Kisqali (ribociclib) is a rival to Pfizer's Ibrance, and both drugs are expected to make a big impact in hormone receptor positive, human epidermal growth factor receptor negative (HR+/HER2 ...

Novartis’ new breast cancer drug Kisqali is set for approval in Europe but like its rival, Pfizer's Ibrance, it could face a struggle for market access in England. Kisqali (ribociclib ...

It appears to affect the CDK4 protein more than the CDK6 protein. Ibrance and Kisqali affect both CDK4 and CDK6 and have to be taken along with hormonal therapy. They are also given in four-week ...

Apart from Pfizer’s Ibrance, Olema is evaluating palazestrant in combination with Kisqali (ribociclib), another CDK4/6 inhibitor marketed by Novartis NVS, in a phase Ib/II study. Management also ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...